Search

Your search keyword '"Fishman, E.K."' showing total 26 results
Start Over Author "Fishman, E.K." Search Limiters Available in Library Collection
26 results on '"Fishman, E.K."'

11. MA03.04 An Integrated Deep Learning Method to Predict Lung Cancer Recurrence Risk for Resected Stage IA NSCLC

Author

Huang, P., primary, Illei, P.B., additional, Franklin, W., additional, Wu, P.-H., additional, Forde, P.M., additional, Ashrafinia, S., additional, Hu, C., additional, Kong, X., additional, Khan, H., additional, Vadvala, H., additional, Shih, I.-M., additional, Battafarano, R., additional, Jacobs, M.A., additional, Chen, Y., additional, Housseau, F., additional, Rahmim, A., additional, Fishman, E.K., additional, Ettinger, D.S., additional, Pienta, K.J., additional, Wirtz, D., additional, Brock, M.V., additional, Gabrielson, E., additional, and Lam, S., additional

Published
2022
Full Text
View/download PDF

14. Impact of liver disease and parenchymal changes on patterns of liver recurrence in patients with resected PDAC: a new insight into the biological behavior of this lethal disease

Author

Javed, A.A., primary, Baig, E., additional, Habib, J.R., additional, C, Correa, additional, Lafaro, K., additional, Greer, J.B., additional, Burkhart, R.A., additional, Burns, W.R., additional, Cohen, S.M., additional, Fishman, E.K., additional, Cameron, J.L., additional, He, J., additional, Weiss, M.J., additional, and Wolfgang, C.L., additional

Published
2021
Full Text
View/download PDF

15. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium

Author

Goggins, M., Overbeek, K.A., Brand, R., Syngal, S., Chiaro, M. del, Bartsch, D.K., Bassi, C., Carrato, A., Farrell, J., Fishman, E.K., Fockens, P., Gress, T.M., Hooft, J.E. van, Hruban, R.H., Kastrinos, F., Klein, A., Lennon, A.M., Lucas, A., Park, W., Rustgi, A., Simeone, D., Stoffel, E., Vasen, H.F.A., Cahen, D.L., Canto, M.I., Bruno, M., Arcidiacono, P.G., Ashida, R., Ausems, M., Besselink, M., Biermann, K., Bonsing, B., Brentnall, T., Chak, A., Early, D., Fernandez-Del Castillo, C., Frucht, H., Furukawa, T., Gallinger, S., Geurts, J., Koerkamp, B.G., Hammel, P., Hes, F., Iglesias-Garcia, J., Kamel, I., Kitano, M., Kloppel, G., Krak, N., Kurtz, R., Kwon, R., Lachter, J., Lee, J., Levy, M., Malleo, G., Meguid, C., Maitra, A., Margolis, D., Offerhaus, J., Olson, S., Paiella, S., Petersen, G., Poley, J.W., Real, F.X., Saltzman, J., Schulick, R., Stoita, A., Takaori, K., Tanaka, M., Tamm, E., Topazian, M., Vazquez-Sequeiros, E., Vleggaar, F., Cappel, W.D.T.N., Yeo, C., Wasser, M., Wagner, A., Wallace, M., Wolfgang, C., Wood, L., Int Canc Pancreas Screening, Goggins, M., Overbeek, K. A., Brand, R., Syngal, S., Del Chiaro, M., Bartsch, D. K., Bassi, C., Carrato, A., Farrell, J., Fishman, E. K., Fockens, P., Gress, T. M., Van Hooft, J. E., Hruban, R. H., Kastrinos, F., Klein, A., Lennon, A. M., Lucas, A., Park, W., Rustgi, A., Simeone, D., Stoffel, E., Vasen, H. F. A., Cahen, D. L., Canto, M. I., Bruno, M, Arcidiacono, P. G., Gastroenterology & Hepatology, Clinical sciences, Medical Genetics, Gastroenterology and Hepatology, AGEM - Digestive immunity, AGEM - Re-generation and cancer of the digestive system, and CCA - Cancer Treatment and Quality of Life

Subjects
Endoscopic ultrasound, medicine.medical_specialty, Biomedical Research, MEDLINE, pancreatic ductal adenocarcinoma, familial pancreatic cancer, Biomedical Research/methods, Article, Germline mutation, Mass Screening/methods, SDG 3 - Good Health and Well-being, Risk Factors, Pancreatic cancer, medicine, Humans, Mass Screening, Pancreatic Neoplasms/diagnosis, Age Factor, Genetic Predisposition to Disease, Family history, Intensive care medicine, early detection, Early Detection of Cancer, Germ-Line Mutation, Medicine(all), Hereditary pancreatitis, medicine.diagnostic_test, business.industry, Carcinoma, Age Factors, Gastroenterology, Pancreatic Neoplasm, Cancer, medicine.disease, Carcinoma/diagnosis, Population Surveillance/methods, Pancreatic Neoplasms, medicine.anatomical_structure, Population Surveillance, surveillance, Early Detection of Cancer/methods, business, Pancreas, genetic predisposition, Human
Abstract

Background and aimThe International Cancer of the Pancreas Screening Consortium met in 2018 to update its consensus recommendations for the management of individuals with increased risk of pancreatic cancer based on family history or germline mutation status (high-risk individuals).MethodsA modified Delphi approach was employed to reach consensus among a multidisciplinary group of experts who voted on consensus statements. Consensus was considered reached if ≥75% agreed or disagreed.ResultsConsensus was reached on 55 statements. The main goals of surveillance (to identify high-grade dysplastic precursor lesions and T1N0M0 pancreatic cancer) remained unchanged. Experts agreed that for those with familial risk, surveillance should start no earlier than age 50 or 10 years earlier than the youngest relative with pancreatic cancer, but were split on whether to start at age 50 or 55. Germline ATM mutation carriers with one affected first-degree relative are now considered eligible for surveillance. Experts agreed that preferred surveillance tests are endoscopic ultrasound and MRI/magnetic retrograde cholangiopancreatography, but no consensus was reached on how to alternate these modalities. Annual surveillance is recommended in the absence of concerning lesions. Main areas of disagreement included if and how surveillance should be performed for hereditary pancreatitis, and the management of indeterminate lesions.ConclusionsPancreatic surveillance is recommended for selected high-risk individuals to detect early pancreatic cancer and its high-grade precursors, but should be performed in a research setting by multidisciplinary teams in centres with appropriate expertise. Until more evidence supporting these recommendations is available, the benefits, risks and costs of surveillance of pancreatic surveillance need additional evaluation.

Published
2020

19. Erratum to “Annotated normal CT data of the abdomen for deep learning: Challenges and strategies for implementation” [Diagn. Interv. Imaging. 101 (2020) 35–44]

Author

Park, S., primary, Chu, L.C., additional, Fishman, E.K., additional, Yuille, A.L., additional, Vogelstein, B., additional, Kinzler, K.W., additional, Horton, K.M., additional, Hruban, R.H., additional, Zinreich, E.S., additional, Fouladi, D.F., additional, Shayesteh, S., additional, Graves, J., additional, and Kawamoto, S., additional

Published
2020
Full Text
View/download PDF

26. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach

Author

Canto, M.I., Goggins, M., Yeo, C.J., Griffin, C., Axilbund, J.E., Brune, K., Ali, S.Z., Jagannath, S., Petersen, G.M., Fishman, E.K., Piantadosi, S., Giardiello, F.M., and Hruban, R.H.

Abstract

Background & Aims: Relatives of patients with pancreatic cancer and persons with certain inherited syndromes are at increased risk for developing pancreatic cancer. We prospectively evaluated the feasibility of screening for pancreatic neoplasia in high-risk individuals. Methods: Individuals from familial pancreatic cancer kindreds and a patient with Peutz-Jeghers syndrome underwent screening endoscopic ultrasound (EUS). If the EUS was abnormal, EUS-guided fine-needle aspiration, endoscopic retrograde cholangiopancreatography (ERCP), and spiral computed tomography (CT) were performed. Patients with abnormalities suggesting neoplasia had surgery. Results: Thirty-eight patients were studied; 31 (mean age, 58 yr; 42% men) from kindreds with >=3 affected with pancreatic cancer; 6 from kindreds with 2 affected relatives, 1 was a patient with Peutz-Jeghers syndrome. None had symptoms referable to the pancreas or suggestive of malignancy. Six pancreatic masses were found by EUS: 1 invasive ductal adenocarcinoma, 1 benign intraductal papillary mucinous neoplasm, 2 serous cystadenomas, and 2 nonneoplastic masses. Hence, the diagnostic yield for detecting clinically significant pancreatic neoplasms was 5.3% (2 of 38). The 1 patient with pancreatic cancer was treated and still is alive and disease-free >5 years after surgery. EUS changes similar to those associated with chronic pancreatitis were found, which were more common in patients with a history of regular alcohol intake (P = 0.02), but also occurred in patients who did not consume alcohol. Screening also led to a new diagnosis and treatment of symptomatic upper-gastrointestinal conditions in 18.4% of patients. Conclusions: EUS-based screening of asymptomatic high-risk individuals can detect prevalent resectable pancreatic neoplasia but false-positive diagnoses also occur.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results